Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
At Hospital/Institution:  Presbyterian - St. Luke's Medical Center
Keywords/Phrases:  leukemia
Trial Status:  Active
Results 1-20 of 20 for your search:
Start Over
Risk-Adapted Chemotherapy in Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia
Phase: Phase III
Type: Supportive care, Treatment
Status: Active
Age: 1 to < 10
Sponsor: NCI, Other
Protocol IDs: AALL0932, NCI-2011-02599, CDR0000683227, U10CA098543, COG-AALL0932, NCT01190930
Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Under 30
Sponsor: NCI
Protocol IDs: NCI-2011-02670, COG-AAML1031, CDR0000701850, AAML1031, U10CA180886, U10CA098543, NCT01371981
Risk-Based Classification System of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Phase: No phase specified
Type: Health services research, Tissue collection/Repository
Status: Active
Age: 30 and under
Sponsor: NCI, Other
Protocol IDs: AALL08B1, NCI-2011-02235, CDR0000674844, COG-AALL08B1, U10CA180886, U10CA098543, NCT01142427
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 1 to 30
Sponsor: NCI, Other
Protocol IDs: AALL1131, NCI-2011-03797, CDR0000706370, U10CA098543, COG-AALL1131, NCT01406756
Caspofungin Acetate or Fluconazole in Preventing Invasive Fungal Infections in Patients With Acute Myeloid Leukemia Who Are Undergoing Chemotherapy
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care
Status: Active
Age: 3 months to 30 years
Sponsor: NCI, Other
Protocol IDs: ACCL0933, NCI-2011-02640, CDR0000695748, COG-ACCL0933, U10CA095861, NCT01307579
Collecting and Storing Samples of Bone Marrow and Blood From Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma
Phase: No phase specified
Type: Tissue collection/Repository
Status: Active
Age: Under 31
Sponsor: NCI, Other
Protocol IDs: AALL05B1, COG-AALL05B1, CDR0000491159, NCT00897325
Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 65 and over
Sponsor: NCI
Protocol IDs: NCI-2013-01220, ALLIANCE A041202, A041202, U10CA180821, U10CA031946, NCT01886872
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 70
Sponsor: NCI
Protocol IDs: NCI-2014-00118, ECOG-E1912, E1912, U10CA180820, U10CA021115, NCT02048813
Combination Chemotherapy With or Without Rituximab in Treating Younger Patients With Stage III-IV Non-Hodgkin Lymphoma or B-Cell Acute Leukemia
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and under
Sponsor: NCI, Other
Protocol IDs: ANHL1131, NCI-2012-01963, CDR0000732604, IGR2009/1593, 2010-019224-31, U10CA098543, U10CA180886, COG-ANHL1131, NCT01595048
Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer
Phase: No phase specified
Type: Tissue collection/Repository
Status: Active
Age: 0 months to 30 year
Sponsor: NCI, Other
Protocol IDs: ABTR01B1, NCI-2009-00324, COG-ABTR01B1, U10CA098543, NCT00898079
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies
Phase: No phase specified
Type: Natural history/Epidemiology
Status: Active
Age: 30 and under
Sponsor: NCI, Other
Protocol IDs: ALTE05N1, NCI-2009-00382, CDR0000590123, U10CA180886, U10CA098543, COG-ALTE05N1, NCT00736749
Sirolimus, Cyclosporine, and Mycophenolate Mofetil In Preventing Graft-Versus-Host Disease in Treating Patients With Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant
Phase: Phase II
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Status: Active
Age: Not specified
Sponsor: NCI, Other
Protocol IDs: 2206.00, NCI-2010-02222, P30CA015704, P01CA018029, NCT01251575
Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies
Phase: Phase II
Type: Biomarker/Laboratory analysis, Supportive care
Status: Active
Age: 0 to 75
Sponsor: NCI, Other
Protocol IDs: 2546.00, NCI-2011-03828, P30CA015704, P01CA018029, NCT01527045
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Status: Active
Age: not specified
Sponsor: NCI, Other
Protocol IDs: 2448.00, NCI-2010-02035, P01CA018029, P30CA015704, NCT01231412
Collecting and Storing Tissue From Young Patients With Cancer
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Tissue collection/Repository
Status: Active
Age: 21 and under
Sponsor: NCI, Other
Protocol IDs: ABTR04B1, COG-ABTR04B1, NCI-2009-00326, NCT00898755
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-01173, CDR0000634119, ECOG-E2905, E2905, U10CA180820, U10CA021115, NCT00843882
Three Different Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000588879, CALGB-30610, RTOG 0538, U10CA031946, NCT00632853
Pemetrexed Disodium or Observation in Treating Patients With Malignant Pleural Mesothelioma Without Progressive Disease After First-Line Chemotherapy
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000667496, CALGB-30901, NCT01085630
Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000675693, CALGB-80702, CALGB-SWOG-C80702, NCT01150045
Study of Blood Samples From Newborns With Down Syndrome
Phase: No phase specified
Type: Biomarker/Laboratory analysis
Status: Active
Age: Under 90 days at diagnosis
Sponsor: NCI, Other
Protocol IDs: AAML08B1, COG-AAML08B1, CDR0000636115, NCI-2011-02193, NCT00959283
Start Over